RGNX vs RARE โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RARE Captures Institutional Edge (2โ2 Pillars ยท 6โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Ultragenyx Pharmaceutical Inc. (RARE) driven by superior Valuation, Growth & Margin while RGNX counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, RGNX trades at N/M Forward P/E with -120.4% operating margin (-69.2% YoY revenue) versus RARE at 11.2x Forward P/E and -59.9% operating margin (+8.1% YoY). In options structure, RGNX sits in BREAKDOWN (52nd %ile IV; Dealer Gamma Walls on Pro) against RARE sits in BREAKDOWN (38th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RGNX Revenue | RARE Revenue | RGNX Op. Margin | RARE Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $220M | $50M | 40.3% | -721.2% | RGNX |
| FY2019 | $40M | $100M | -422.9% | -409.0% | RARE |
| FY2020 | $150M | $270M | -77.1% | -121.8% | RGNX |
| FY2021 | $470M | $350M | 34.0% | -108.6% | RGNX |
| FY2022 | $110M | $360M | -233.2% | -178.6% | RARE |
| FY2023 | $90M | $430M | -297.1% | -131.1% | RARE |
| FY2024 | $80M | $560M | -280.0% | -95.7% | RARE |
| FY2025 | $170M | $670M | -94.6% | -79.5% | RARE |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RGNX | RARE | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $500.9M | $1.7B | Larger Scale | RARE |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | 11.2x | Lower Multiple | RARE |
| Revenue Growth (YoY) Growth | -69.2% | +8.1% | Higher Growth | RARE |
| Operating Margin (TTM) Profitability | -120.4% | -59.9% | Higher Margin | RARE |
| Net Profit Margin Profitability | -113.9% | -71.8% | Higher Margin | RARE |
| Return on Equity (ROE) Capital Efficiency | -113.2% | -608.5% | Higher ROE | RGNX |
| 52-Week Range Position Momentum | 19% ($5โ$16) | 12% ($13โ$40) | Stronger Trend | RGNX |
| Beta / 30D Volatility Risk Regime | 1.82ฮฒ ยท 76% Vol | 1.40ฮฒ ยท 57% Vol | Lower Realized Risk | RARE |
| Unified Institutional Score Composite Signal | 45.3 / 100 (HOLD) | 43.8 / 100 (HOLD) | Higher Composite | RGNX |